Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.
|Articles|January 8, 2015
CTCL Treatments - The Old and New - Part 2
Part 2 of an overview and explanation of current cutaneous lymphoma treatments.
Advertisement
Alain H. Rook, MD, Professor of Dermatology, University of Pennsylvania, Perelman School of Medicine provides part two of a three part overview of treatments for cutaneous lymphoma.
Advertisement
Related to this article
At the 2026 National Summit on Hematologic Cancers, Kate Kennedy, MSN, APRN, flagged decisions where guidelines give nurses and APPs little direction.
Interim AYA-NAV data show most navigation components reached young patients with cancer as designed, though full sessions lagged during treatment.
Kate Kennedy, MSN, APRN, explains how Vanderbilt-Ingram's award-winning APP clinic moved bispecific step-up dosing out of the hospital.
By 26 months, 81% of families of children with B-ALL reported job or marital changes; less frequent maintenance pulses eased expenses only.
Nurses and NPs share how they manage rash, stomatitis, diarrhea, dose holds, cost, and trial eligibility with oral daraxonrasib in pancreatic cancer.
As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.
Nicole Doell, MSN, RN, of Sylvester explains how nurses can address breast cancer misinformation without judgment and share vetted resources.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Daraxonrasib and RAS Inhibition: What Oncology Nurses Need to Know
2
Inside an APP-Led Outpatient Clinic for Bispecific Step-Up Dosing
3
AYA Needs Navigation Trial Meets Most Fidelity Targets at Interim Look
4
October 2026 FDA Approvals: 7 Cancer Updates for Oncology Nurses
5